The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study

• Published in: International journal of urology 2024-04, Vol.31 (4), p.394-401
• Main Authors: Nakano, Juria, Urabe, Fumihiko, Kiuchi, Yuria, Takamizawa, Shigeyoshi, Suzuki, Hirotaka, Kawano, Shota, Miyajima, Keiichiro, Fukuokaya, Wataru, Takahashi, Kazuhiro, Iwatani, Kosuke, Imai, Yu, Kayano, Sotaro, Aikawa, Koichi, Yanagisawa, Takafumi, Tashiro, Kojiro, Yuen, Steffi, Sato, Shun, Tsuzuki, Shunsuke, Miki, Jun, Kimura, Takahiro
• Format: Article
• Language: English
• Subjects: Biopsy; Bladder cancer; Chemotherapy; intravesical recurrence; Invasiveness; Patients; Risk factors; upper tract urothelial carcinoma; ureteroscopy; Urothelial carcinoma
• ISSN: 0919-8172; 1442-2042
• DOI: 10.1111/iju.15375

Background With the development of kidney‐sparing surgery and neoadjuvant chemotherapy, ureteroscopic biopsy (URSBx) has become important for the management of upper tract urothelial carcinoma (UTUC). Methods We retrospectively analyzed data from 744 patients with UTUC who underwent radical nephroureterectomy (RNU), stratified into no ureteroscopy (URS), URS alone, and URSBx groups. Intravesical recurrence‐free survival (IVRFS) was examined using the Kaplan–Meier method. We conducted Cox regression analyses to identify risk factors for IVR. We investigated differences between clinical and pathological staging to assess the ability to predict the pathological tumor stage and grade of RNU specimens. Results Kaplan–Meier curves and multivariate Cox regression revealed significantly more IVR and inferior IVRFS in patients who underwent URS and URSBx. Superficial, but not invasive, bladder cancer recurrence was more frequent in the URS and URSBx groups than in the no URS group. Clinical and pathological staging agreed for 55 (32.4%) patients. Downstaging occurred for 48 (28.2%) patients and clinical understaging occurred for 67 (39.4%) patients. Upstaging to muscle‐invasive disease occurred for 39 (35.8%) of 109 patients with ≤cT1 disease. Clinical and pathological grading were similar for 72 (42.3%) patients. Downgrading occurred for 5 (2.9%) patients, and clinical undergrading occurred for 93 (54.7%) patients. Conclusion URS and URSBx instrumentation will be risk factors for superficial, but not invasive, bladder cancer recurrence. Clinical understaging/undergrading and upstaging to muscle‐invasive disease occurred for a large proportion of patients with UTUC who underwent RNU. These data emphasize the challenges involved in accurate UTUC staging and grading.